17952-83-9

Usage

InChI:InChI=1/C11H9ClN2O/c12-6-1-2-9-8(5-6)7-3-4-13-11(15)10(7)14-9/h1-2,5,14H,3-4H2,(H,13,15)

Upstream product

• 3731-16-6 3-carboethoxy-2-pyridone 
• 17216-62-5 diethyl 2-(2-cyanoethyl)malonate 
• 106-47-8 4-chloro-aniline 
• 41888-21-5 3-carboxy-2-piperidone 
• 91089-98-4 piperidine-2,3-dione-3-(4-chloro-phenylhydrazone) 

Downstream Products

• 682802-84-2 2-(5-chloro-1-methyl-1H-indol-3-yl)ethanamine 
• 3764-94-1 5-chlorotryptamine 
• 1053744-89-0 (3aS,4S,6R,6aR)-6-(6-{2-[5-Chloro-1-(2,5-dimethyl-benzyl)-1H-indol-3-yl]-ethylamino}-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid cyclopropylamide 
• 174727-65-2 2-[5-Chloro-1-(2,5-dimethyl-benzyl)-1H-indol-3-yl]-ethylamine 
• 942-26-7 5-chlorotryptamine hydrochloride 

Relevant academic research and scientific papers

ALLOSTERIC MODULATORS OF THE CANNIBINOID 1 RECEPTOR

The present technology relates to compounds and compositions of Formulas I, II, VII, and VIII, and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of addiction, metabolic syndrome, obesity, and/or a CB1 receptor-medited disorder.

CARBAZOLE, CARBOLINE, AND INDOLE DERIVATIVES USEFUL IN THE INHIBITION OF VEGF PRODUCTION

In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds and compositions useful in the inhibition of BEGF production, and/or in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

Synthesis and cytotoxic activity of novel quinazolino-β-carboline-5- one derivatives

A novel series of quinazolino-β-carbolinone derivatives was synthesized and evaluated for their in vitro and in vivo anticancer activity. Many compounds have shown good in vitro activity in the range 1-8μM concentration. Three of the compounds were further tested in nude mice bearing HT-29 colon cancer xenografts.

N6-Substituted Adenosine Receptor Agonists. Synthesis and Pharmacological Activity as Potent Antinociceptive Agents

Novel N6-(indol-3-yl)alkyl derivatives of adenosine were synthesized.The adenosine receptor affinity and the antinociceptive activity of these compounds were assessed in binding studies and the phenylbenzoquinone-induced writhing test.Most of these analogues exhibited a potent analgesic activity without side effects.Among them, compound 3c (UP 202-32) bound to A1 (Ki = 110 nM) and A2 (Ki = 350 nM) adenosine receptors in a specific manner since it did not interact with many other receptors, especially opioid binding sites.The antinociceptive activity in the phenylbenzoquinone assay (ED50 = 3.3 mg/kg po) was antagonized by 8-cyclopentyltheophylline, suggesting that an adenosinergic mechanism underlies the analgesic activity observed with this compound.The data obtained with these new N6-substituted adenosine receptor agonists emphasize the interest of such compounds in the treatment of pain.